Details for Patent: 5,731,312
✉ Email this page to a colleague
| Title: | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| Abstract: | A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects. |
| Inventor(s): | Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA) |
| Assignee: | The Board of Supervisors of Louisiana State University and Agricultural (Baton Rouge, LA) Ergo Research Corporation (Wakefield, RI) |
| Filing Date: | Jun 06, 1995 |
| Application Number: | 08/468,528 |
| Claims: | 1. In a method for treating one or more of obesity, insulin resistance, hyperinsulinemia, or hyperglycemia in a vertebrate by administration of a dopamine agonist or prolactin inhibitor, the improvement which comprises: confining the delivery of said dopamine agonist or prolactin inhibitor to the period during the day proximate to the time of day at which the serum prolactin concentration of lean, insulin-sensitive vertebrates of the same species is low; and additionally administering to said vertebrate a therapeutically effective amount of a prolactin stimulator in a dosage regimen under which the delivery of said prolactin stimulator is confined to the period during the day after the time at which the serum prolactin concentration of lean, insulin-sensitive vertebrates of the same species reaches its point of maximum depression and prior to the time of day when said prolactin concentration rises to a peak in lean, insulin-sensitive vertebrates of the same species. 2. An improvement according to claim 1 in which the vertebrate being treated is a human and the delivery of said prolactin inhibitor or dopamine agonist is confined proximate to the time of waking and the delivery of said prolactin stimulator is confined proximate to the time of onset of sleeping. 3. An improvement according to claim 2 in which said dopamine agonist or prolactin inhibitor is bromocriptine. 4. An improvement according to claim 3 in which said prolactin stimulator is metoclopramide. 5. A method for treating obesity, insulin resistance, hyperinsulinemia, or hyperglycemia in a vertebrate, which comprises: administering a first therapeutic amount of a dopamine agonist or prolactin inhibitor to said vertebrate in a dosage regimen under which delivery of said dopamine agonist or prolactin inhibitor is confined to the period during the day proximate to the time of day at which the serum prolactin concentration of lean, insulin-sensitive vertebrates of the same species is low, and administering to said vertebrate a second therapeutically effective amount of a prolactin stimulator in a dosage regimen under which the delivery of said prolactin stimulator is confined to the period of the day after the time at which the serum prolactin concentration of lean, insulin-sensitive vertebrates of the same species reaches its point of maximum depression and prior to the time of day when said prolactin concentration rises to a peak in lean insulin-sensitive vertebrates of the same species. 6. A method according to claim 5 in which the vertebrate being treated is a human and the delivery of said prolactin inhibitor or dopamine agonist is confined proximate to the time of waking and the delivery of said prolactin stimulator is confined proximate to the time of onset of sleeping. 7. A method according to claim 6 in which said dopamine agonist or prolactin inhibitor is bromocriptine. 8. A method according to claim 7 in which said prolactin inhibitor is metoclopramide. |
